FDA APPROVES NEW TREATMENT FOR ADVANCED PROSTATE CANCER PATIENTS Print
News Releases - Health, Medicine & Nutrition
Written by Zero - the end of prostate cancer   
Monday, 20 May 2013 14:21

The FDA has approved Bayer and Algeta's drug Xofigo (radium Ra 223 dichloride, formerly known as alpharadin) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.

Xofigo binds with minerals in the bone to deliver radiation directly to bone tumors, limiting the damage to the surrounding normal tissues. It is the second prostate cancer drug approved by the FDA in the past year that demonstrates an ability to extend the survival of men with metastatic prostate cancer.

Patients who are interested in finding out where and when newly FDA approved drug Xofigo will be available can call 1-855-696-3446 (1-855-6Xofigo) or visit the website www.xofigo.com.